

ANDA 75-114

July 26, 1999

Abbott Laboratories  
Hospital Products Division  
Attention: Thomas P. Sampogna  
200 Abbott Park Road, D-389 AP30  
Abbott Park, IL 60064-3537

Dear Sir:

This is in reference to your abbreviated new drug application dated April 18, 1997, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Acyclovir Injection, 50 mg/mL (500 mg/10 mL and 1 g/20 mL plastic vials).

Reference is also made to your amendments dated December 31, 1998; and February 2, February 11, and March 15, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The drug product, Acyclovir Injection 50 mg/mL, can be expected to have the same therapeutic effect as that of the listed drug product upon which the Agency relied as the basis of safety and effectiveness.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

Page 2

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Douglas L. Sporn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research